SureTrader Advertisement
Home > Boards > US Listed > Biotechs > Ariad Pharmaceuticals, Inc. (ARIA)

A relevant excerpt from the patent application:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
iandy Member Profile
 
Followed By 18
Posts 2,999
Boards Moderated 0
Alias Born 06/09/10
160x600 placeholder
ARIAD Announces Webcast of Its Annual Stockholders Meeting "Business Wire" - 6/24/2016 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/23/2016 4:13:32 PM
ARIAD Completes Strategic Review and Announces Plans for Growth "Business Wire" - 6/17/2016 12:33:00 PM
ARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North Africa "Business Wire" - 6/17/2016 7:45:00 AM
ARIAD Initiates Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration Ahead of Plan "Business Wire" - 6/17/2016 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/15/2016 4:20:44 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/14/2016 6:14:12 PM
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial "Business Wire" - 6/13/2016 7:35:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 6/8/2016 4:11:40 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/8/2016 4:10:17 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 6/8/2016 4:08:59 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 6/8/2016 4:08:08 PM
ARIAD to Host Analyst & Investor Day in New York City "Business Wire" - 6/8/2016 7:35:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/7/2016 4:09:07 PM
ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate & 12.9-Month Median Pro... "Business Wire" - 6/6/2016 7:35:00 AM
ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Mon... "Business Wire" - 6/4/2016 7:35:00 AM
ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatin... "Business Wire" - 6/4/2016 7:35:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/2/2016 8:31:45 AM
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig® "Business Wire" - 6/2/2016 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/1/2016 4:55:42 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 6/1/2016 4:53:33 PM
ARIAD to Present at the Jefferies 2016 Global Healthcare Conference "Business Wire" - 6/1/2016 7:35:00 AM
ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR & HER2, in Patie... "Business Wire" - 5/31/2016 7:35:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) "Edgar (US Regulatory)" - 5/27/2016 5:16:34 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/26/2016 4:09:04 PM
iandy   Friday, 07/12/13 07:16:59 AM
Re: jaybe post# 32123
Post # of 74216 
A relevant excerpt from the patent application:

>There is no cure for PD. Current therapy relies heavily on replenishing dopamine by giving patients oral doses of a dopaminergic agent like the dopamine precursor levodopa (alone or in the combination carbidopa levodopa) or a dopamine agonist. Such therapy can provide relief, although with the increasing risk of serious side effects and often with diminishing therapeutic results, requiring increasing doses as treatment continues, and more serious side effects. There is a profound need for additional therapeutics for PD.

c-Abl is a major regulator of parkin function and phosphorylates parkin on tyrosine 143. This phosphorylation inhibits parkin's E3 ubiquitin ligase activity leading to

accumulation of AIMP2 and FBP1 and loss of parkin's cytoprotective function and cell death. One Abl inhibitor, STI-571 , has been found to maintain parkin in a catalytically active and neuroprotective state by preventing phosphorylation of parkin. As such, it is believed that inhibition of c-Abl presents a viable approach for the treatment of PD. o, et al., PNAS, 107(38), 16691 -16696 (2010). One challenge of using STI-571 to treat PD is that it has poor penetration of the blood-brain barrier as demonstrated in mice and humans. Thus, there is a need for Abl inhibitors that cross the blood-brain barrier for the treatment of PD.

Applicant's own WO 2007/075869, which is hereby incorporated herein by reference for all purposes, discloses certain compounds that inhibit inter alia Abl. One notable Abl inhibitor is ponatinib, which is currently the subject of a clinical trial to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation of Bcr-Abl (clinical trials.gov identifier NCT01207440). WO 2007/075869 does not explicitly mention using such Abl inhibitors for the treatment of PD.

SUMMARY

It has been unexpectedly discovered that certain Abl inhibitors cross the blood brain barrier and are useful in the regulation of parkin and accordingly for the treatment of PD.<



SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist